A meta-analysis of double-blind randomized controlled trials has examined the adverse effects attributed to statin therapy in product labels. The study's findings suggest that many side effects listed on statin labels may be overstated, with most not actually caused by the drugs. The analysis' results imply that statin labeling may need to be revised to reflect more accurate information about potential side effects.